









Markets
/
Stocks
/
nasdaq-plx
/

Protalix Biotherapeutics Inc

PLX

2.220USD

-0.160-6.72%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

177.01MMarket Cap

28.21P/E TTM



Protalix Biotherapeutics Inc

2.220

-0.160-6.72%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Protalix Biotherapeutics Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Protalix Biotherapeutics Inc's Score

Industry at a Glance

Industry Ranking

68 / 159

Overall Ranking

194 / 4615

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+488.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Protalix Biotherapeutics Inc Highlights

StrengthsRisks

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.40M.

Overvalued

The company’s latest PE is 24.99, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 12.12M shares, increasing 9.87% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.06.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.58, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.66M, representing a year-over-year increase of 16.21%, while its net profit experienced a year-over-year increase of 107.44%.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

7.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

2.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.68

Key Metrics

Free cash flow

No Data

Protalix Biotherapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.20, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 24.99, which is 166.29% below the recent high of 66.55 and 152.66% above the recent low of -13.16.

Score

Industry at a Glance

Previous score

6.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Protalix Biotherapeutics Inc is 14.00, with a high of 15.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

14.000

Target Price

+488.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Protalix Biotherapeutics Inc

PLX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 8.98, which is higher than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 2.66 and the support level at 1.69, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.25

Change

-0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Neutral

RSI(14)

48.090

Neutral

STOCH(KDJ)(9,3,3)

37.163

Sell

ATR(14)

0.159

Low Volatility

CCI(14)

-12.671

Neutral

Williams %R

36.000

Buy

TRIX(12,20)

0.249

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.340

Sell

MA10

2.337

Sell

MA20

2.308

Sell

MA50

2.111

Buy

MA100

1.807

Buy

MA200

2.046

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

HIR Investments Ltd

4.71M

BlackRock Institutional Trust Company, N.A.

3.00M

+1741.73%

Bashan (Dror)

2.28M

Renaissance Technologies LLC

Star Investors

1.62M

+35.83%

Geode Capital Management, L.L.C.

826.33K

Northern Trust Global Investments Limited

689.88K

+0.96%

Rubin (Eyal)

660.91K

+15.95%

Stratos Wealth Partners, Ltd.

350.00K

+1.04%

Connor, Clark & Lunn Investment Management Ltd.

496.22K

+2.76%

The Vanguard Group, Inc.

Star Investors

484.80K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 3.35, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is -0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.